Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2022

Open Access 01-12-2022 | Neuroblastoma | Case report

Malignancies in patients with cystic fibrosis: a case series

Authors: Dorothea Appelt, Teresa Fuchs, Gratiana Steinkamp, Helmut Ellemunter

Published in: Journal of Medical Case Reports | Issue 1/2022

Login to get access

Abstract

Background

Previous reports have shown an increased number of colorectal cancers in patients with cystic fibrosis. We assessed the database of our cystic fibrosis center to identify patients with all kinds of cancer retrospectively. All patients visiting the Cystic Fibrosis Centre Innsbruck between 1995 and 2019 were included.

Case presentation

Among 229 patients with cystic fibrosis treated at the Cystic Fibrosis Centre in Innsbruck between 1995 and 2019, 11 subjects were diagnosed with a malignant disease. The median age at diagnosis was 25.2 years (mean 24.3 years). There were four gynecological malignancies (cervical intraepithelial neoplasia and cervical cancer), two hematological malignancies (acute lymphocytic leukemia), one gastrointestinal malignancy (peritoneal mesothelioma), and four malignancies from other origins (malignant melanoma, neuroblastoma, adrenocortical carcinoma, and thyroid cancer). One malignancy occurred after lung transplantation. There was a strong preponderance of females, with 10 of the 11 cases occurring in women. Six deaths were attributed to cancer.

Conclusions

Most diagnoses were made below 30 years of age, and half of the subjects died from the malignant disease. Awareness of a possible malignancy is needed in patients with atypical symptoms. Regular screenings for cancer should also be considered, not only for gastrointestinal tumors.
Literature
1.
go back to reference Parkins MD, Parkins VM, Rendall JC, Elborn S. Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population. Ther Adv Respir Dis. 2011;5(2):105–19.CrossRef Parkins MD, Parkins VM, Rendall JC, Elborn S. Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population. Ther Adv Respir Dis. 2011;5(2):105–19.CrossRef
2.
go back to reference Neglia JP, Wielinski CL, Warwick WJ. Cancer risk among patients with cystic fibrosis. J Pediatr. 1991;119(5):764–6.CrossRef Neglia JP, Wielinski CL, Warwick WJ. Cancer risk among patients with cystic fibrosis. J Pediatr. 1991;119(5):764–6.CrossRef
3.
go back to reference Johannesson M, Askling J, Montgomery SM, Ekbom A, Bahmanyar S. Cancer risk among patients with cystic fibrosis and their first-degree relatives. Int J Cancer. 2009;125(12):2953–6.CrossRef Johannesson M, Askling J, Montgomery SM, Ekbom A, Bahmanyar S. Cancer risk among patients with cystic fibrosis and their first-degree relatives. Int J Cancer. 2009;125(12):2953–6.CrossRef
4.
go back to reference Schöni MH, Maisonneuve P, Schöni-Affolter F, Lowenfels AB. Cancer risk in patients with cystic fibrosis: the European data. CF/CSG Group. J R Soc Med. 1996;89(Suppl 27):38–43.PubMedPubMedCentral Schöni MH, Maisonneuve P, Schöni-Affolter F, Lowenfels AB. Cancer risk in patients with cystic fibrosis: the European data. CF/CSG Group. J R Soc Med. 1996;89(Suppl 27):38–43.PubMedPubMedCentral
5.
go back to reference Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst. 2003;95(5):381–7.CrossRef Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW, Lowenfels AB. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst. 2003;95(5):381–7.CrossRef
6.
go back to reference Hough NE, Chapman SJ, Flight WG. Gastrointestinal malignancy in cystic fibrosis. Paediatr Respir Rev. 2020;35:90–2.PubMed Hough NE, Chapman SJ, Flight WG. Gastrointestinal malignancy in cystic fibrosis. Paediatr Respir Rev. 2020;35:90–2.PubMed
7.
go back to reference Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst. 2013;105(2):122–9.CrossRef Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst. 2013;105(2):122–9.CrossRef
8.
go back to reference Neglia JP, FitzSimmons SC, Maisonneuve P, Schöni MH, Schöni-Affolter F, Corey M, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med. 1995;332(8):494–9.CrossRef Neglia JP, FitzSimmons SC, Maisonneuve P, Schöni MH, Schöni-Affolter F, Corey M, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med. 1995;332(8):494–9.CrossRef
9.
go back to reference Sheldon CD, Hodson ME, Carpenter LM, Swerdlow AJ. A cohort study of cystic fibrosis and malignancy. Br J Cancer. 1993;68(5):1025–8.CrossRef Sheldon CD, Hodson ME, Carpenter LM, Swerdlow AJ. A cohort study of cystic fibrosis and malignancy. Br J Cancer. 1993;68(5):1025–8.CrossRef
10.
go back to reference Abraham JM, Taylor CJ. Cystic fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros. 2017;16(Suppl 2):S40–9.CrossRef Abraham JM, Taylor CJ. Cystic fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros. 2017;16(Suppl 2):S40–9.CrossRef
11.
go back to reference Garg M, Ooi CY. The enigmatic gut in cystic fibrosis: linking inflammation, dysbiosis, and the increased risk of malignancy. Curr Gastroenterol Rep. 2017;19(2):6.CrossRef Garg M, Ooi CY. The enigmatic gut in cystic fibrosis: linking inflammation, dysbiosis, and the increased risk of malignancy. Curr Gastroenterol Rep. 2017;19(2):6.CrossRef
12.
go back to reference Hegagi M, Aaron SD, James P, Goel R, Chatterjee A. Increased prevalence of colonic adenomas in patients with cystic fibrosis. J Cyst Fibros. 2017;16(6):759–62.CrossRef Hegagi M, Aaron SD, James P, Goel R, Chatterjee A. Increased prevalence of colonic adenomas in patients with cystic fibrosis. J Cyst Fibros. 2017;16(6):759–62.CrossRef
13.
go back to reference McKenna PB, Mulcahy E, Waldron D. Early onset of colonic adenocarcinoma associated with cystic fibrosis—a case report. Ir Med J. 2006;99(10):310–1.PubMed McKenna PB, Mulcahy E, Waldron D. Early onset of colonic adenocarcinoma associated with cystic fibrosis—a case report. Ir Med J. 2006;99(10):310–1.PubMed
14.
go back to reference Meyer KC, Francois ML, Thomas HK, Radford KL, Hawes DS, Mack TL, et al. Colon cancer in lung transplant recipients with CF: increased risk and results of screening. J Cyst Fibros. 2011;10(5):366–9.CrossRef Meyer KC, Francois ML, Thomas HK, Radford KL, Hawes DS, Mack TL, et al. Colon cancer in lung transplant recipients with CF: increased risk and results of screening. J Cyst Fibros. 2011;10(5):366–9.CrossRef
15.
go back to reference Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):758–67.CrossRef Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):758–67.CrossRef
16.
go back to reference Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203.CrossRef Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203.CrossRef
17.
go back to reference Zolin A, Orenti A, Naehrlich L, Jung A, van Rens J, et al. ECFSPR Annual Report 2018; 2020. Zolin A, Orenti A, Naehrlich L, Jung A, van Rens J, et al. ECFSPR Annual Report 2018; 2020.
18.
go back to reference Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology. 2018;154(3):736-745.e14.CrossRef Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology. 2018;154(3):736-745.e14.CrossRef
20.
go back to reference Tizzano EF, Silver MM, Chitayat D, Benichou JC, Buchwald M. Differential cellular expression of cystic fibrosis transmembrane regulator in human reproductive tissues. Clues for the infertility in patients with cystic fibrosis. Am J Pathol. 1994;144(5):906–14.PubMedPubMedCentral Tizzano EF, Silver MM, Chitayat D, Benichou JC, Buchwald M. Differential cellular expression of cystic fibrosis transmembrane regulator in human reproductive tissues. Clues for the infertility in patients with cystic fibrosis. Am J Pathol. 1994;144(5):906–14.PubMedPubMedCentral
21.
go back to reference Rousset-Jablonski C, Reynaud Q, Nove-Josserand R, Ray-Coquard I, Mekki Y, Golfier F, et al. High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis. Eur J Obstet Gynecol Reprod Biol. 2018;221:40–5.CrossRef Rousset-Jablonski C, Reynaud Q, Nove-Josserand R, Ray-Coquard I, Mekki Y, Golfier F, et al. High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis. Eur J Obstet Gynecol Reprod Biol. 2018;221:40–5.CrossRef
22.
go back to reference Wu Z, Peng X, Li J, Zhang Y, Hu L. Constitutive activation of nuclear factor κB contributes to cystic fibrosis transmembrane conductance regulator expression and promotes human cervical cancer progression and poor prognosis. Int J Gynecol Cancer. 2013;23(5):906–15.CrossRef Wu Z, Peng X, Li J, Zhang Y, Hu L. Constitutive activation of nuclear factor κB contributes to cystic fibrosis transmembrane conductance regulator expression and promotes human cervical cancer progression and poor prognosis. Int J Gynecol Cancer. 2013;23(5):906–15.CrossRef
23.
go back to reference Xia X, Wang J, Liu Y, Yue M. Lower cystic fibrosis transmembrane conductance regulator (CFTR) promotes the proliferation and migration of endometrial carcinoma. Med Sci Monit. 2017;23:966–74.CrossRef Xia X, Wang J, Liu Y, Yue M. Lower cystic fibrosis transmembrane conductance regulator (CFTR) promotes the proliferation and migration of endometrial carcinoma. Med Sci Monit. 2017;23:966–74.CrossRef
24.
go back to reference Edenborough FP. Women with cystic fibrosis and their potential for reproduction. Thorax. 2001;56(8):649–55.CrossRef Edenborough FP. Women with cystic fibrosis and their potential for reproduction. Thorax. 2001;56(8):649–55.CrossRef
25.
go back to reference Amaral MD, Quaresma MC, Pankonien I. What role does CFTR play in development, differentiation, regeneration and cancer? Int J Mol Sci. 2020;21(9):3133.CrossRef Amaral MD, Quaresma MC, Pankonien I. What role does CFTR play in development, differentiation, regeneration and cancer? Int J Mol Sci. 2020;21(9):3133.CrossRef
26.
go back to reference Slae M, Wilschanski M. Cystic fibrosis: a gastrointestinal cancer syndrome. Lancet Oncol. 2018;19(6):719–20.CrossRef Slae M, Wilschanski M. Cystic fibrosis: a gastrointestinal cancer syndrome. Lancet Oncol. 2018;19(6):719–20.CrossRef
27.
go back to reference de González BA, Mahesh M, Kim K-P, Bhargavan M, Lewis R, Mettler F, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071–7.CrossRef de González BA, Mahesh M, Kim K-P, Bhargavan M, Lewis R, Mettler F, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071–7.CrossRef
28.
go back to reference Woods JC, Wild JM, Wielpütz MO, Clancy JP, Hatabu H, Kauczor H-U, et al. Current state of the art MRI for the longitudinal assessment of cystic fibrosis. J Magn Reson Imag. 2019;52:1306–20.CrossRef Woods JC, Wild JM, Wielpütz MO, Clancy JP, Hatabu H, Kauczor H-U, et al. Current state of the art MRI for the longitudinal assessment of cystic fibrosis. J Magn Reson Imag. 2019;52:1306–20.CrossRef
29.
go back to reference Naselli A, Cresta F, Favilli F, Casciaro R. A long-term follow-up of residual mass neuroblastoma in a patient with cystic fibrosis. BMJ Case Rep 2015; 2015. Naselli A, Cresta F, Favilli F, Casciaro R. A long-term follow-up of residual mass neuroblastoma in a patient with cystic fibrosis. BMJ Case Rep 2015; 2015.
30.
go back to reference Moss RB, Blessing-Moore J, Bender SW, Weibel A. Cystic fibrosis and neuroblastoma. Pediatrics. 1985;76(5):814–7.CrossRef Moss RB, Blessing-Moore J, Bender SW, Weibel A. Cystic fibrosis and neuroblastoma. Pediatrics. 1985;76(5):814–7.CrossRef
31.
go back to reference Xu J, Yong M, Li J, Dong X, Yu T, Fu X, et al. High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo. Oncol Rep. 2015;33(5):2227–34.CrossRef Xu J, Yong M, Li J, Dong X, Yu T, Fu X, et al. High level of CFTR expression is associated with tumor aggression and knockdown of CFTR suppresses proliferation of ovarian cancer in vitro and in vivo. Oncol Rep. 2015;33(5):2227–34.CrossRef
Metadata
Title
Malignancies in patients with cystic fibrosis: a case series
Authors
Dorothea Appelt
Teresa Fuchs
Gratiana Steinkamp
Helmut Ellemunter
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2022
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-021-03234-1

Other articles of this Issue 1/2022

Journal of Medical Case Reports 1/2022 Go to the issue